about
Childhood acute myeloid leukaemiaThe clinically relevant pharmacogenomic changes in acute myelogenous leukemiaProgress in acute myeloid leukemiaAn overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatmentFLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?Targeted immunotherapy for acute myeloid leukemiaAcute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITDTreatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.The Future of Targeting FLT3 Activation in AML.Treatment of FLT3-ITD acute myeloid leukemia.SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells.Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice.Rational Combinations of Targeted Agents in AMLQuantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length.Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse.Effect of FLT3 ligand on survival and disease phenotype in murine models harboring a FLT3 internal tandem duplication mutation.Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.FLT3 inhibitors: clinical potential in acute myeloid leukemia.NT1721, a novel epidithiodiketopiperazine, exhibits potent in vitro and in vivo efficacy against acute myeloid leukemia.FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments.Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia.Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.Outcome of older patients with acute myeloid leukemia in first relapse.Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers.Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients.
P2860
Q27005960-1A317EE4-BDBF-4E0A-99BE-752E34A4611DQ27014790-4CEAC985-E9DF-4F87-B8E0-774456E45FAAQ27024006-5A12B8E1-2F67-4702-98F4-67B4BBA113A5Q27027207-C8102E0C-C41B-4C15-B522-7B1E0B3969CFQ27028163-B15BB06A-E119-45AD-BE89-65335888329BQ27687636-2BDF40F5-D5FC-470F-B2B6-B86BC2BBF698Q27851694-8064C33B-51D3-4744-A59A-D0BEF876061DQ33798909-45F8C927-C2F7-4AE9-B353-EED89A971A25Q34011740-D6BED3EF-9A67-4019-B160-6B5688B98098Q34289202-1571ECBC-F0BF-48E2-A077-CBC183BA4026Q34555386-F6C1D7D4-5B42-43CE-9C1F-27FE7B018F64Q34636735-2143B07C-4E7B-434A-BAC7-EEAE5385A6C1Q35009327-B92CB3E9-221E-45A3-82DD-06C9E4898EF7Q35144330-53154A8B-A078-4D8B-8E10-0F70DA0752C7Q35750491-36EEEE18-28A0-49E4-B2C2-4B552BD17E2EQ36022521-2E9BB7E3-9682-4FEA-8F3F-677B1BF99FCAQ36862461-01165F51-2796-4374-818E-9C01390A3791Q36949028-030C51FF-2A88-4644-8ABC-C4FFB1A2E7BEQ37244802-E5172944-1126-4D10-AC85-8B0AE65B329DQ37638749-B521680F-0F77-4735-BD6F-BCF841C4CF2BQ37699211-86D49B4C-E8BB-40B3-BD1E-FC140BE7EF03Q38101284-73CB6360-9293-4A45-B87A-131DE2FA3A90Q38155455-27A30828-54F5-4B86-87B8-309F3D99E186Q38241988-7C79877A-1D9F-4C6A-ABDD-D77426E27C66Q39135512-AA7F5814-B693-40BA-A457-EA28C5BF038EQ39405204-FFA2364D-896B-404F-8566-FBCEF173C905Q39674948-F07A01D1-AE44-4032-ACE1-0902FA6FCE76Q44425255-897F1504-5693-462E-887E-F255383F2650Q54505356-EB5C888D-37E4-4B24-BA3B-8AB31915E199
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
FLT3/ITD AML and the law of unintended consequences.
@ast
FLT3/ITD AML and the law of unintended consequences.
@en
type
label
FLT3/ITD AML and the law of unintended consequences.
@ast
FLT3/ITD AML and the law of unintended consequences.
@en
prefLabel
FLT3/ITD AML and the law of unintended consequences.
@ast
FLT3/ITD AML and the law of unintended consequences.
@en
P2860
P1433
P1476
FLT3/ITD AML and the law of unintended consequences.
@en
P2093
Mark Levis
P2860
P304
P356
10.1182/BLOOD-2011-03-340273
P407
P577
2011-05-17T00:00:00Z